trending Market Intelligence /marketintelligence/en/news-insights/trending/MwbPkZgsITR0qBdN1gYltA2 content esgSubNav
In This List

Loxo Oncology starts rolling submission of FDA application for cancer drug

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Loxo Oncology starts rolling submission of FDA application for cancer drug

Loxo Oncology Inc. initiated the submission of a rolling new drug application to the U.S. Food and Drug Administration for its cancer treatment larotrectinib.

Larotrectinib is intended for treating unresectable or metastatic solid tumors with NTRK-fusion proteins in patients who require systemic therapy and have either progressed following prior treatment or have no acceptable alternative treatments.

The company expects to complete the submission in early 2018.